ANAB Stock Analysis: Buy, Sell, or Hold?

ANAB - AnaptysBio, Inc. Common Stock

PHARMACEUTICAL PREPARATIONS
$59.43
-0.56 (-0.93%) ▼
5d: -0.13%
30d: -1.62%
90d: -5.25%
BUY
HIGH Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 05, 2026

Get Alerted When ANAB Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.
100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading chart...

Loading historical data...

💡
Bottom Line:
✅ BUY SIGNAL: ANAB shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
See Forward Earnings Fair Value & Price Prediction →

Long-Term Wealth Forecast (2031)

Based on Analyst Consensus Growth & Historical Valuation

0% (Stagnation) 50% (Hyper Growth)
EST. PRICE IN 2031
$81.43
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$50.56
Trading above historical range

How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 11.1x Exit PE.

In-depth Analysis How we analyze

Valuation Analysis: ANAB is currently trading at $59.43, which is considered slightly high relative to its 30-day fair value range of $52.71 to $59.90. The stock's valuation (Forward PE: 11.3) is in line with its historical norms (11.1). At these levels, the market is pricing in 0.8% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.

Technical Outlook: Technically, ANAB is in a uptrend. Immediate support is located at $50.59, while resistance sits at $62.32.

Market Sentiment: ANAB has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $87.09 (+46.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.

Quick Decision Summary

Current Position SLIGHTLY HIGH
Historical Trading Range $52.71 - $59.90
Company Quality Score 58/100 (HOLD)
Options IV Signal 43th percentile (NORMAL)
Volume Confirmation HIGH
Confidence Score 75.8%

All Signals

  • NEUTRAL: Options fairly priced (IV 43th percentile)
  • BULLISH: Strong technical setup (60/100)
  • BULLISH: High volume confirmation
  • BULLISH: Trading 46.5% below Wall St target ($87.09)
  • NEUTRAL: Market pricing in 0.8% annual earnings growth - fairly valued

Trading Range Analysis

30-Day Trading Range $52.71 - $59.90
Current vs Trading Range SLIGHTLY HIGH
Expected Move (7 Days) ±$7.09 (11.9%)

Support & Resistance Levels

Support Level $50.59
Resistance Level $62.32
Current Trend Uptrend
Technical data as of Jun 23, 2026

Fundamental Context

Forward P/E (Next Year Est.) 11.35
Wall Street Target $87.09 (+46.5%)
Revenue Growth (YoY) -8.0%
Profit Margin -11.5%
Valuation Premium vs History +0.8% premium
PE vs Historical 11.4 vs 11.1 FAIR
Market-Implied Price Targets If current PE multiple persists
Implied Growth (YoY): +0.8% (market-implied from PE analysis)
1-Year Target $59.91 (+1%)
2-Year Target $60.38 (+2%)
3-Year Target $60.87 (+2%)
3-Yr Target (if PE normalizes) (PE: 11→11) PE COMPRESSION $59.52 (+0%)
Earnings growth offset by PE compression
Share & Embed Analysis

Found this analysis useful? Share it with your community or embed the live chart on your blog.

Tweet Reddit
bloggers & journalists: you are free to use our charts with attribution.
Last updated: June 23, 2026 6:30 PM ET
Data refreshes hourly during market hours. Next update: 7:30 PM
🔥 Top Stocks Breaking Out Now
Ticker Score Recommendation Change %
Technical Signals Check
Insider Activity (6 Months)
0
Buys
16
Sells
Net
INSIDERS SELLING
Recent Transactions
John P Schmid SELL 20645 shares 2026-03-30
Daniel Faga SELL 17679 shares 2026-03-27
Eric J Loumeau SELL 10000 shares 2026-02-11

Unlock Insider Activity

See real-time buying/selling by company executives for ANAB.

Create Free Account

Already have an account? Log In

Top Rated Biotechnology Stocks

Top-rated stocks in Biotechnology by analyst ratings.

Stock Analyst Consensus Analyst Target Tradestie Score
REGN
Regeneron Pharmaceutical…
STRONG BUY
25 analysts
$833 67 BUY
XENE
Xenon Pharmaceuticals Inc
STRONG BUY
19 analysts
$81 67 BUY
IONS
Ionis Pharmaceuticals Inc
BUY
26 analysts
$105 64 BUY
BBIO
BridgeBio Pharma Inc
STRONG BUY
19 analysts
$102 65 BUY
JAZZ
Jazz Pharmaceuticals PLC
STRONG BUY
18 analysts
$257 59 HOLD

More Analysis for ANAB

ANAB Technical Chart ANAB Price Prediction ANAB Earnings Date ANAB Investment Advisor ANAB Fair Price Analyzer ANAB Competitors
Live Trades
From trading groups
Loading trades...
View All Live Trades See Trader Consensus & Signals